MSU
IBB icon

Maple Securities USA’s iShares Biotechnology ETF IBB Stock Holding History

Maple Securities USA’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,944
Closed -$223K – 264
2015
Q1 		$223K Buy
+1,944
New +$214K 0.02% 209

Other funds holding IBB

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Maple Securities USA's IBB Position: Q2 2015 in Review

Maple Securities USA sold out of iShares Biotechnology ETF (IBB) in Q2 2015, closing a stake of 1,944 shares — an estimated $223K sold.

Maple Securities USA first reported a position in IBB in Q1 2015 and held it in 1 quarter. The position peaked at $223K in Q1 2015. 419 funds tracked by Wall St. Rank hold IBB as of Q2 2015.

  • Maple Securities USA reported no remaining iShares Biotechnology ETF position as of Q2 2015 after selling out during the quarter.
  • Maple Securities USA sold 1,944 iShares Biotechnology ETF shares in Q2 2015, an estimated $223K.
  • Maple Securities USA first reported a position in iShares Biotechnology ETF in Q1 2015 and held it in 1 quarter.
  • Maple Securities USA's iShares Biotechnology ETF position peaked at $223K in Q1 2015.
  • 419 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2015.

Based on Maple Securities USA's 13F filing for Q2 2015, filed 24 Jul 2015.